Ldl Cholesterol

Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.

In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.”

The National Lipid Association Scientific Sessions will be held today to Sunday and will spotlight statements on nutrition in adults with dyslipidemia, include sessions on the integration of lipid guidelines in clinical practice and more.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.

Comparing a treat-to-target statin strategy with a high-intensity strategy for people with CAD.

About 75% of adults with heterozygous familial hypercholesterolemia do not meet guideline-recommended LDL treatment targets, whereas women with familial hypercholesterolemia are less likely than men to be appropriately treated, data show.

The American College of Cardiology Scientific Session was held March 4 to 6 in New Orleans. Healio | Cardiology Today was on-site for the latest news in cardiology and experts’ reactions to it.

NEW ORLEANS — Among adults with CAD, a treat-to-target LDL strategy of 50 mg/dL to 70 mg/dL was noninferior to a high-intensity statin therapy for the 3-year composite of death, MI, stroke or coronary revascularization, researchers wrote.